Medicine

Michael Goldberg PhD '08 founded Surge Therapeutics, a company developing a hydrogel immunotherapy treatment aimed at reducing the risk of surgically-removed cancers returning, reports India Rice for Forbes. “Broadly speaking, immunotherapy is a range of cancer treatments that aim to strengthen the immune system’s ability to fight cancer,” explains Rice. “But what makes Surge’s solution different is that it’s applied during surgery as opposed to other immunotherapies that are delivered weeks before or weeks after surgery.”

Prof. Regina Barzilay speaks with Nicole Estephan of WCVB-TV’s Chronicle about her work developing new AI systems that could be used to help diagnose breast and lung cancer before the cancers are detectable to the human eye.

Prof. Jon Gruber speaks with Boston Public Radio hosts Jim Braude and Margery Eagen about the economics behind the Ozempic phenomenon, an antidiabetic drug being used to manage weight loss. “This is very new phenomenon and I think we are just starting to grapple with it,” says Gruber. “I think one positive aspect… it will put pressure on Congress to once again think more seriously about broader price of drug reform.”

Prof. Kevin Esvelt and his students have found that language-generating AI models could make it easier to create pandemic potential pathogens, reports Kelsey Piper for Vox.

MIT researchers and an undergraduate class found that chatbots could be prompted to suggest pandemic pathogens, including specific information not commonly known among experts, reports Ryan Health for Axios. The MIT researchers recommend "pre-release evaluations of LLMs by third parties, curating training datasets to remove harmful concepts, and verifiably screening all DNA generated by synthesis providers or used by contract research organizations."

Science reporter Robert F. Service spotlights how Prof. Kevin Esvelt is sounding the alarm that “AI could help somebody with no science background and evil intentions design and order a virus capable of unleashing a pandemic.” 

Researchers at MIT have developed an ingestible pill that can raise levels of hormones to help increase appetite and decrease nausea, reports Maggie Chen for Wired. The researchers “hope that it can one day act as an effective noninvasive therapy for those who experience gastroparesis—or other eating disorders—essentially being a temporary switch that can be activated to drive hunger and digestion,” writes Chen.

Prof. Marzyeh Ghassemi speaks with NPR host Kate Wells about a decision by the National Eating Disorders Associations to replace their helpline with a chatbot. “I think it's very alienating to have an interactive system present you with irrelevant or what can feel like tangential information,” says Ghassemi.

Principal Research Scientist Ana Jaklenec speaks with CBC host Bob McDonald about her work developing a mobile vaccine printer. The device “can be very important in certain scenarios when you’re trying to bring the ability to vaccinate in areas that might not have the right infrastructure to make vaccines or even to administer vaccines,” says Jaklenec, “so I think the portability is key here.” 

Soledad O’Brien spotlights how researchers from MIT and Massachusetts General Hospital developed a new artificial intelligence tool, called Sybil, that an accurately predict a patient’s risk of developing lung cancer. “Sybil predicted with 86 to 94 percent accuracy whether a patient would develop lung cancer within a year,” says O’Brien.

Prof. Gio Traverso and colleagues at NYU have developed an electronic pill that could stimulate appetite. The device delivers small pulses of electricity that “induce the release of ghrelin, the body’s so-called “hunger hormone,” which is involved in regulating appetite and alleviating severe nausea and vomiting,” reports Joanna Thompson for Inverse.

Prof. Marzyeh Ghassemi speaks with NPR host Emily Kwong and correspondent Geoff Brumfiel about how artificial intelligence could impact medicine. “When you take state-of-the-art machine-learning methods and systems and then evaluate them on different patient groups, they do not perform equally,” says Ghassemi.

Research from MIT and elsewhere have developed a mobile app that uses computer-vision techniques and AI to detect post-surgery signs of infection as part of an effort to help community workers in Kirehe, a district in Rwanda’s Eastern province, reports Shefali Malhotra for Science. “The researchers are now improving the app so it can be used across more diverse populations such as in Ghana and parts of South America,” writes Malhotra.

Researchers from MIT and NYU have “developed a first-of-its-kind treatment to help spur hunger via stimulating hormone levels in the gut—an “electroceutical” ingestible capsule inspired by a “water wicking” reptile,” writes Andrew Paul for Popular Science. “The team explored a novel way to “significantly and repeatedly” induce the production of ghrelin, a hormone that triggers hunger.”

Researchers at MIT have developed a new nanoparticle sensor that can detect cancerous proteins through a simple urine test. “The researchers designed the tests to be done on a strip of paper, similar to the at-home COVID tests everyone became familiar with during the pandemic,” writes Lambert. “They hope to make it as affordable and accessible to as many patients as possible.”